medigraphic.com
ISSN 1561-2988 (Print)

2021, Number 4

<< Back Next >>

Rev Cubana Farm 2021; 54 (4)

Potential drug-laboratory test interactions in patients hospitalized in an intensive care unit

Sosa Fernández-Aballí L, Marcillo VÁA, Cedeño ML, Cabrera MD, Howland ÁI, Oviedo MC

Language: Spanish
References: 25
Page: 1-15
PDF size: 711.03 Kb.


ABSTRACT

Introduction: Patients hospitalized in an intensive care unit are under treatment with multiple drugs, which can interfere with the results of laboratory tests, and lead to misdiagnosis, incorrect treatment and unnecessary additional tests.
Objective: Identify potential drug-laboratory test interactions in patients hospitalized in the intensive care unit of ¨Dr. Verdi Cevallos Balda¨ Regional Hospital.
Methods: A descriptive and retrospective study was conducted. The medical records of patients hospitalized in the intensive care unit were reviewed, in the period January 2018 to September 2019. Once the data were obtained, a literature search was carried out for the drugs that may cause alterations in the results of the laboratory tests and the frequency of the potential interactions between the laboratory tests and the most used drugs was determined.
Results: In total, 1585 tests were registered and 1485 potential druglaboratory interactions related to the biological effect of the drugs were detected. It was appreciated that the same test may be subject to interference from several drugs or the same drug may affect several determinations. Furosemide was the most involved drug in potential interactions and the omeprazole-transaminase glutamic oxalacetic and metoclopramide-serum glucose pairs were the most frequent.
Conclusions: In patients hospitalized in the intensive care unit, there is a high prevalence of potential interactions between laboratory tests and administered drugs, either due to the amount prescribed or due to the high frequency of tests in which they interfere. The possibility of an interaction appearing does not mean that it does so constantly, but it is important that they are taken into account in the interpretations of laboratory results.


REFERENCES

  1. Yao H, Rayburn ER, Shi Q, Gao L, Hu W, Li H. FDA-approved drugs thatinterfere with laboratory tests: A systematic search of US drug labels. Crit RevClin Lab Sci. 2017;54(1):1-17. DOI: 10.1080/10408363.2016.1191425

  2. Van Balveren J, Verboeket-Van De Venne W, Erdem-Eraslan L, de Graaf A,Loot A, Musson R, et al. Diagnostic error as a result of drug-laboratory testinteractions. Diagnosis. 2019;6(1):69-71. DOI: https://doi.org/10.1515/dx-2018-0098

  3. Van Balveren J, Verboeket-van De Venne W, Doggen C, Cornelissen A,Erdem-Eraslan L, de Graaf A, et al. Clinical usefulness of drug-laboratory testinteraction alerts: a multicentre survey. Clinical Chemistry and LaboratoryMedicine (CCLM). 2021;59(7):1239-45. DOI: 10.1515/cclm-2020-1770

  4. Van Balveren J, Verboeket-Van De Venne W, Erdem-Eraslan L, De Graaf A,Loot A, Musson R, et al. Impact of interactions between drugs and laboratorytest results on diagnostic test interpretation-a systematic review. Clin ChemLab Med. 2018;56(12):2004-9. DOI: 10.1515/cclm-2018-0900

  5. Ortiz Y, García MM, Rosales KK, Vázquez Y, Fonseca E. Interferencias demedicamentos con pruebas de laboratorios. Rev Cubana Farm. 2005 [acceso10/01/2020];39(3). Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75152005000300012

  6. Young DS. Effects of drugs on clinical laboratory tests. Ann Clin Biochem.1997;34(6):579-81. DOI: 10.1177/000456329703400601

  7. Terleira A, Portolés A, Rojas A, Vargas E. Effect of drug-test interactions onlength of hospital stay. Pharmacoepidemiol Drug Saf. 2007;16(1):39-45. DOI:https://doi.org/10.1002/pds.1330

  8. Munive LMR, Simón DJI, Oropeza CR. Interferencia entre medicamentos ypruebas de laboratorio en pacientes hospitalizados. Experiencia del CentroMédico ABC. Rev Mex Patol Clin Med Lab. 2009 [acceso10/01/2020];56(4):265-70. Disponible en:https://www.medigraphic.com/pdfs/patol/pt-2009/pt094f.pdf

  9. Silva R, Domingueti C, Tinoco M, Veloso J, Pereira M, Baldoni A, et al.Interference of medicines in laboratory exams. J. Bras. Patol. Med. Lab.2021;57:1-15. DOI: https://doi.org/10.5935/1676-2444.20210014

  10. CIMA [sede web]. Madrid: Agencia Española de Medicamentos y ProductosSanitarios; 2014 [acceso 12/06/2021]. Disponible en:https://cima.aemps.es/cima/publico/home.html

  11. PLM. Diccionario de Especialidades Farmacéuticas PLM. México: Para LosMédicos; 2019 [acceso 12/06/2021]. Disponible en:https://www.medicamentosplm.com

  12. Ecuador. Ministerio de Salud Pública. Resolución No. 4889 del 10 de juniode 2014. Ministerio de Salud Pública: Ecuador; 2014 [acceso 12/02/2020].Disponible en: https://www.controlsanitario.gob.ec/wpcontent/uploads/downloads/2018/12/AM-%204889_Reglamento-para-laaprobacion-y-seguimiento-de-CEISH-y-CEAS.pdf

  13. Dnyaneshwar M, Ghuge Balasaheb Eknathrao K. Study of moderate tosevere hyponatremia in patients admitted to medical intensive care units(MICU) in a tertiary care hospital. MedPulse Int J Med. 2020;16(3):111-4. DOI:https://doi.org/10.26611/10211636

  14. Terleira A. Interacciones entre medicamentos y pruebas de laboratorio enlos servicios de medicina Interna [tesis doctoral]. [Madrid]: UniversidadComplutense de Madrid; 2003 [acceso 10/01/2021];60(2):98-103. Disponibleen: https://eprints.ucm.es/id/eprint/2964/

  15. Carrillo M, Aular Y, Espinoza M, Arenas E. Potenciales interaccionesfármacos – pruebas de laboratorio en pacientes con patologíascardiovasculares hospitalizados. Revista Academia. 2014 [acceso12/02/2020];13(32):23-34. Disponible en:http://erevistas.saber.ula.ve/index.php/academia/article/view/6718/6565

  16. Iavecchia L, Cereza García G, Sabaté Gallego M, Vidal Guitart X, RamosTerrades N, de la Torre J, et al. Insuficiencia renal aguda relacionada conmedicamentos en pacientes hospitalizados. Nefrología. 2015;35(6):523-32.DOI: https://doi.org/10.1016/j.nefroe.2016.01.001

  17. Khajavi Rad A, Mohebbati R, Hosseinian S. Drug-induced nephrotoxicityand medicinal plants. Iran J Kidney Dis. 2017 [acceso 23/06/2020];11(3):169-79. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28575877/

  18. Arancibia JM. Estrategias para el uso de antibióticos en pacientes críticos.Rev Médica Clínica Las Condes. 2019;30(2):151-9. DOI:https://doi.org/10.1016/j.rmclc.2019.03.001

  19. Barros A, Mesquita A, Aguiar T, Brasil F, & Morais, I. Lesão hepáticainduzida por medicamentos: Qual o papel do farmacêutico clínico? Rev BrasFarmácia Hosp e Serviços Saúde. 2016 [acceso 30/07/2020];7(4):31-5.Disponible en:http://rbfhss.saude.ws/revista/arquivos/2016070405000954BR.pdf

  20. Montrief T, Koyfman A, Long B. Acute liver failure: A review foremergency physicians. Am J Emerg Med. 2019;37(2):329-37. DOI:https://doi.org/10.1016/j.ajem.2018.10.032

  21. Vargas R, Torné N, Travé P, March M, Rodríguez G, Calero S. Revisión delas interferencias entre los medicamentos más prescritos en el servicio deatención primaria de L’Hospitalet de Llobregat (ICS) y los análisis clínicos.Atención Primaria. 2006;37(3):133-41. DOI: https://doi.org/10.1157/13085340

  22. Leitoles PJN de C, Lenhardt MM, Silva BK de F, Tenfen A. InteraçõesFisiológicas Causadas Por Medicamentos Em Exames Bioquímicos De PerfilRenal E Hepático/ Physiological Interactions Caused By Drugs in BiochemicalTests of Renal and Hepatic Profile. Brazilian J Dev. 2021;7(1):10329-48. DOI:10.34117/BJDV7N1-702

  23. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Glycemiccontrol, mortality, and hypoglycemia in critically ill patients: a systematicreview and network meta-analysis of randomized controlled trials. IntensiveCare Med. 2017;43(1):1-15. DOI: 10.1007 / s00134-016-4523-0

  24. Meyer-Gerspach AC, Cajacob L, Riva D, Herzog R, Drewe J, Beglinger C, etal. Mechanisms regulating insulin response to intragastric glucose in lean andnon-diabetic obese subjects: A randomized, double-blind, parallel-group trial.PLoS One. 2016;11(3):1-19. DOI: 10.1371/journal.pone.0150803

  25. Gutiérrez-Hermosillo H, Díaz de León-González E, Beltrán Santiago D,Armando Cedillo-Rodríguez J, Gutiérrez Hermosillo V, Taméz-Pérez HE.Metoclopramida, factor de riesgo para hiperglucemia postprandial en diabetestipo 2. Nutr Hosp. 2012;27(4):1267-71. DOI: 10.3305/nh.2012.27.4.5607




2020     |     www.medigraphic.com